Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822977 · ClinicalTrials.gov registry record · Phase 1
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01822977: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01822977 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01822977, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of clostridium difficile infection (CDI).
Interventions
- DRUG omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822977
The ClinicalTrials.gov registry entry for NCT01822977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which omeprazole is the first listed.
NCT01822977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822977 about?
NCT01822977 is a clinical study titled "The Impact of Proton Pump Inhibitors on the Fecal Microbiome". The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of clostridium difficile infection (CDI).
What is the current status of trial NCT01822977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-03. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01822977?
The interventions under investigation include: omeprazole (DRUG).
Who is sponsoring clinical trial NCT01822977?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.